Publications
Detailed Information
Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, E-K | - |
dc.contributor.author | Lee, E. J. | - |
dc.contributor.author | Lee, S-H | - |
dc.contributor.author | Koo, K. H. | - |
dc.contributor.author | Hwang, E. H. | - |
dc.contributor.author | Kim, C-W | - |
dc.contributor.author | Park, B-K | - |
dc.contributor.author | Kim, Y-N | - |
dc.contributor.author | Jeong, K-C | - |
dc.contributor.author | Park, J. H. | - |
dc.contributor.author | Sung, J. Y. | - |
dc.date.accessioned | 2012-05-31T02:15:18Z | - |
dc.date.available | 2012-05-31T02:15:18Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | BRITISH JOURNAL OF PHARMACOLOGY; Vol.160 5; 1212-1223 | ko_KR |
dc.identifier.issn | 0007-1188 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76656 | - |
dc.description.abstract | Background and purpose: Lipid rafts and caveolae are membrane microdomains with important roles in cell survival signalling involving the Akt pathway. Cholesterol is important for the structure and function of these microdomains. The ginsenoside Rh2 exhibits anti-tumour activity. Because Rh2 is structurally similar to cholesterol, we investigated the possibility that Rh2 exerted its anti-tumour effect by modulating rafts and caveolae. Experimental approach: A431 cells (human epidermoid carcinoma cell line) were treated with Rh2 and the effects on cell apoptosis, raft localization and Akt activation measured. We also examined the effects of over-expression of Akt and active-Akt on Rh2-induced cell death. Key results: Rh2 induced apoptosis concentration- and time-dependently. Rh2 reduced the levels of rafts and caveolae in the plasma membrane and increased their internalization. Furthermore, Akt activity was decreased and consequently, Akt-dependent phosphorylation of Bad, a pro-survival protein, was decreased whereas the pro-apoptotic proteins, Bim and Bax, were increased upon Rh2 treatment. Unlike microdomain internalization induce by cholesterol depletion, Rh2-mediated internalization of rafts and caveolae was not reversed by cholesterol addition. Also, cholesterol addition did not restore Akt activation or rescue cells from Rh2-induced cell death. Rh2-induced cell death was attenuated in MDA-MB-231 cells over-expressing either wild-type or dominant-active Akt. Conclusions and implications: Rh2 induced internalization of rafts and caveolae, leading to Akt inactivation, and ultimately apoptosis. Because elevated levels of membrane rafts and caveolae, and Akt activation have been correlated with cancer development, internalization of these microdomains by Rh2 could potentially be used as an anti-cancer therapy. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | lipid rafts and caveolae | ko_KR |
dc.subject | apoptosis | ko_KR |
dc.subject | cholesterol | ko_KR |
dc.subject | Akt | ko_KR |
dc.subject | ginsenosides | ko_KR |
dc.title | Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1111/j.1476-5381.2010.00768.x | - |
dc.citation.journaltitle | BRITISH JOURNAL OF PHARMACOLOGY | - |
dc.description.citedreference | Musende AG, 2009, CANCER CHEMOTH PHARM, V64, P1085, DOI 10.1007/s00280-009-0965-1 | - |
dc.description.citedreference | Park EK, 2009, J PATHOL, V218, P337, DOI 10.1002/path.2531 | - |
dc.description.citedreference | Royer MC, 2009, J BIOL CHEM, V284, P15826, DOI 10.1074/jbc.M808641200 | - |
dc.description.citedreference | YI JS, 2009, BIOCHEM BIOPH RES CO, V24, P154 | - |
dc.description.citedreference | Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313 | - |
dc.description.citedreference | Lasserre R, 2008, NAT CHEM BIOL, V4, P538, DOI 10.1038/nchembio.103 | - |
dc.description.citedreference | Tarahovsky YS, 2008, MOL CELL BIOCHEM, V314, P65, DOI 10.1007/s11010-008-9766-9 | - |
dc.description.citedreference | Giannoni E, 2008, CELL DEATH DIFFER, V15, P867, DOI 10.1038/cdd.2008.3 | - |
dc.description.citedreference | Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002 | - |
dc.description.citedreference | Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308 | - |
dc.description.citedreference | McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001 | - |
dc.description.citedreference | Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/008-5472.CAN-07-0288 | - |
dc.description.citedreference | Schley PD, 2007, J NUTR, V137, P548 | - |
dc.description.citedreference | Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7 | - |
dc.description.citedreference | YUE PY, 2007, CHIN MED, V2, P6 | - |
dc.description.citedreference | Ham YM, 2006, J PHARMACOL EXP THER, V319, P1276, DOI 10.1124/jpet.106.109926 | - |
dc.description.citedreference | Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925 | - |
dc.description.citedreference | Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959 | - |
dc.description.citedreference | LI YC, 2006, AM J PATHOL, V168, P1404 | - |
dc.description.citedreference | del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293 | - |
dc.description.citedreference | Cheng CC, 2005, CANCER CHEMOTH PHARM, V55, P531, DOI 10.1007/s00280-004-0919-6 | - |
dc.description.citedreference | Zhuang LY, 2005, J CLIN INVEST, V115, P959 | - |
dc.description.citedreference | Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549 | - |
dc.description.citedreference | Kim YS, 2004, ARCH PHARM RES, V27, P834 | - |
dc.description.citedreference | Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672 | - |
dc.description.citedreference | Ham YM, 2003, J BIOL CHEM, V278, P50330, DOI 10.1074/jbc.M302997200 | - |
dc.description.citedreference | Rubio CA, 2003, EUR J CLIN INVEST, V33, P406 | - |
dc.description.citedreference | Zhuang LY, 2002, CANCER RES, V62, P2227 | - |
dc.description.citedreference | Kim YN, 2000, J BIOL CHEM, V275, P7481 | - |
dc.description.citedreference | Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9 | - |
dc.description.citedreference | Nakata H, 1998, JPN J CANCER RES, V89, P733 | - |
dc.description.citedreference | Salvioli S, 1997, FEBS LETT, V411, P77 | - |
dc.description.citedreference | TODE T, 1993, J CANCER RES CLIN, V120, P24 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.